Next 10 |
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-25 06:45:00 ET Summary Alnylam has been extremely persistent over the years in getting their RNA interference ideas developed and tested. That original RNAi therapy (patisiran) was directed towards neuropathy, but Alnylam has been hoping that such treatments would show ben...
2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...
2024-06-12 10:55:44 ET More on Alnylam Pharmaceuticals Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentatio...
2024-06-07 15:09:58 ET More on Alnylam, Pliant, etc. Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation ...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO...
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDAQ:BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional inf...
2024-06-04 14:46:03 ET Summary Revolution Medicines, Inc. stock has more than doubled since the market initially reacted negatively to a clinical update on its lead asset RMC-6236 in October 2023. The company's RAS(ON) inhibitors will be tested in two registrational trials for pan...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO...